AbbVie announced that the European Commission has approved SKYRIZI for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy. SKYRIZI (150 mg) is approved to be administered by two subcutaneous injections every 12 weeks following two initiation doses at week 0 and week 4. In clinical studies, SKYRIZI demonstrated high rates of skin clearance at 16 weeks and this clearance was durable at one year. This approval allows for the marketing of SKYRIZI in all member states of the European Union, as well as Iceland, Liechtenstein and Norway.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.